Samsung Biologics to Acquire PolyPeptide Group for $1.8B, Expanding CDMO Capabilities into Peptide Therapeutics with $2.2B Capital Raise

September 6, 2026

Endpoints News South Korea

Overview

Samsung Biologics announced a capital raise of nearly $2.2 billion to fund its long-term growth strategy, including the acquisition of PolyPeptide Group for $1.8 billion. This acquisition will significantly expand Samsung’s CDMO capabilities beyond antibodies and ADCs to encompass peptide therapeutics, leveraging PolyPeptide’s global network of six cGMP facilities. The remaining funds will be allocated to the expansion of its Bio Campus II, further diversifying its contract manufacturing services and bolstering its competitive edge in the biopharmaceutical market.

In Depth

Key Findings

Samsung Biologics has announced a substantial capital raise of approximately $2.2 billion, primarily to finance its strategic acquisition of PolyPeptide Group for $1.8 billion. This landmark deal is set to dramatically expand Samsung’s Contract Development and Manufacturing Organization (CDMO) capabilities, extending its service offerings beyond traditional antibodies and antibody-drug conjugates (ADCs) into the burgeoning field of peptide therapeutics.

Technical / Clinical Details

Business Diversification: Samsung Biologics is a prominent player in the biopharmaceutical CDMO market, but this acquisition will mark its entry into the peptide therapeutics modality. Peptides represent a high-growth area, with significant applications in obesity treatments (e.g., GLP-1 agonists), oncology, and rare diseases.
Strengthened Manufacturing Network: PolyPeptide Group boasts a global network of six Current Good Manufacturing Practice (cGMP)-compliant facilities, specializing in peptide manufacturing. This acquisition instantaneously grants Samsung Biologics top-tier capabilities and a global footprint in peptide production, enabling it to offer more comprehensive CDMO services to its clients.
Fund Allocation: Of the approximately $2.2 billion raised, $1.8 billion will be dedicated to the acquisition of PolyPeptide Group. The remaining funds are earmarked for the expansion of Samsung’s existing Bio Campus II, indicating a simultaneous intent to enhance capabilities in its established biopharmaceutical operations, such as antibody production.

Background & Context

The biopharmaceutical market is undergoing rapid expansion driven by the emergence of diverse therapeutic modalities, with peptide therapeutics gaining significant attention for their specificity and efficacy. The CDMO sector is indispensable in supporting the development and manufacturing of these complex drugs, where comprehensive service offerings are crucial for competitive advantage.

Samsung Biologics’ acquisition represents a strategic move to differentiate its services from competitors and cater to a broader spectrum of client needs. This indicates a clear ambition to establish itself as a “one-stop shop” for biopharmaceutical manufacturing.

Strategic Significance & Outlook

The acquisition of PolyPeptide Group is a transformative transaction for Samsung Biologics, achieving both portfolio diversification and a significant expansion of its global manufacturing footprint. This move will secure new revenue streams in the high-growth peptide therapeutics market and is expected to create synergies with its existing antibody and ADC businesses. This action will likely accelerate the trend of M&A activity within the CDMO industry and the pursuit of more integrated service offerings. Ultimately, patients are expected to benefit from the faster market introduction of a wider range of therapeutic options.

Source: #

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.